| Vivus: Is the Ship Sinking? KLLJ Investments submits: Ask any of the major analysts on the buy-side of Vivus (VVUS,) and you will hear that Qnexa is the next mega-blockbuster. Its 37lb’s of weight loss is so impressive, it is sure to be a multi-billion dollar drug. Wall Street has driven up the price from a 52-week low of $4.18 all the way up to a recent high of $13.68. Even $13.68 is cheap if you are talking about a mega-blockbuster! In my blog entry regarding who will be the First Line Therapy for Obesity, I discussed many of the reasons why Qnexa won’t be that drug and why.It seems that the Vivus insider who should have the most confidence on the success of Qnexa agrees with me. VVUS filed today yet another Form 4 for Leland Wilson, this time selling another 50,000 shares at a pre-determined price of $13. Basically, Leland had decided that $13 was a very fair price for VVUS, generous even perhaps, so he filed a 105b-1 that said when VVUS hits $13, I’ll sell 50,000 shares. This follows major selling of VVUS by the CEO in 2009, before and after Phase III results for Qnexa came out. These include the following transactions.Complete Story » seekingalpha.com |
A Radical View on Giving Statins Some prominent doctors are pushing a heretical notion: Physicians have been prescribing statins to some of the wrong people. online.wsj.com |
Arena's Obesity Drug Likely to Pass FDA Panel With Flying Colors Rockford Coscia submits:This year a trio of obesity drugs has stormed onto the stage and they will soon face their respective FDA decisions. The trio consists of Vivus’ (VVUS) Qnexa, which was already voted down by an FDA panel, Arena’s (ARNA) Lorcaserin, and Orexigen’s (OREX) Contrave. Following Qnexa’s jilting by FDA panel, many investors piled into Arena as lorcaserin’s side effect profile appeared the most benign of the three. Lorcaserin faces its own FDA panel on September 16. While I’m guessing that multiple issues will be discussed – including potential off-label use with fentermine – one of the issues likely to be addressed is the potential of valvulopathy in long-term use of lorcaserin. There is very good reason to believe, however, that these concerns will be little more than a distraction on the way to lorcaserin’s approval.Complete Story » seekingalpha.com |
Procoralan® Reduces Heart Failure Death, Hospitalisation Risk - Video PROCORALAN® REDUCES RISK OF DEATH AND HOSPITALISATION FOR HEART FAILURE IN CHRONIC HEART FAILURE PATIENTS BY MORE THAN A QUARTER feedproxy.google.com |
Amylin, Alkermes Hit Hard on Surprise Bydureon Rejection Other GLP-1s Coming Up Fast About the only good news for Amylin Pharmaceuticals Inc. Wednesday was that investors were unlikely to pay mind to the fact that third-quarter sales of diabetes drug Byetta (exenatide) missed analyst expectations, as shares of the San Diego-based biotech were hammered on a complete response letter and the prospect of a two-year delay for its once-weekly version of the GLP-1 agonist.Complete Story » seekingalpha.com |